spesolimab   Click here for help

GtoPdb Ligand ID: 12169

Synonyms: BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Approved drug Immunopharmacology Ligand
spesolimab is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Spesolimab (BI-655130) is a monoclonal antibody that disrupts interleukin-36 (IL-36)/IL-36 receptor signalling. Blocking this pathway is a molecular mechanism with potential to treat inflammatory diseases in skin and other epithelial tissues [2-3,5,7], since IL-36R expression is restricted to epithelial cells that are in direct contact with the environment, including those in the skin. Spesolimab (BI-655130) appears to be related to MAB92 which was reported by Boehringer Ingelheim in 2017 [6], but we have been unable to perform direct sequence matches. The heavy and light chain sequences for spesolimab (from its INN record) are claimed in Boehringer Ingelheim's patent US9023995B2 [4].
Click here for help
No information available.
Summary of Clinical Use Click here for help
The FDA approved spesolimab (Spevigo®; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis (GPP) flares in September 2022.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02978690 BI655130 Single Dose in Generalized Pustular Psoriasis Phase 1 Interventional Boehringer Ingelheim 2
NCT03782792 Effisayilâ„¢ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Phase 2 Interventional Boehringer Ingelheim 1